NEW DATA ILLUSTRATE NOVEL MECHANISM OF ACTION OF LAQUINIMOD, AN ORAL COMPOUND FOR THE TREATMENT OF MULTIPLE SCLEROSIS
April 28, 2009 15:00 (CEST)|
Contact: |
Elana Holzman Kevin Mannix |
Teva Pharmaceutical Industries Ltd. Teva North America |
+972-(3)-926-7554 +1-(215)-591-8912 |
|
Contact: |
Tomas Leanderson Göran Forsberg |
Active Biotech AB
Active Biotech AB |
+46-46-19-20-95
+46-46-19-11-54
|
Jerusalem, Israel, Lund, Sweden and Seattle, Washington, April 28, 2009 - Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and Active Biotech (NASDAQ OMX NORDIC: ACTI) today announced results from several new clinical and preclinical studies providing further insight on the immunomodulatory mechanism of action (MOA) of laquinimod, a novel oral once-daily compound being developed for the treatment of relapsing-remitting multiple sclerosis (RRMS). Four sets of data being presented at the 61st Annual American Academy of Neurology Meeting (AAN) in Seattle stand to increase the understanding of how laquinimod may reduce multiple sclerosis activity and affect mechanisms related to disease pathology.